Long-term comparative effectiveness of first-line infliximab vs corticosteroids in ulcerative colitis: Remission and colectomy risk

Table 1 Demographic and baseline clinical and laboratory characteristics of both groups, median (interquartile range)/n (%)

Characteristics	Group 1 (IFX), n = 68	Group 2 (IVCS), n = 71	P value
Age (years)	49 (45, 55)	55 (49, 62)	0.101
Gender			0.487
Male	41 (60.3)	47 (66.2)
Female	27 (39.7)	24 (33.8)
Body weight (kg)	68.5 (65, 82)	70 (66, 90)	0.422
Smoking habits			0.950
Heavy smoker	10 (14.7)	9 (12.7)
Moderate smoker	9 (13.2)	9 (12.7)
Ex smoker	13 (19.1)	12 (16.9)
Nonsmoker	36 (52.9)	41 (57.7)
Family history of IBD			0.832
Crohn’s disease	10 (14.7)	8 (11.3)
UC	12 (17.6)	16 (22.5)
UC extent (Montreal)			0.655
E1 (proctitis)	21 (30.9)	17 (23.9)
E2 (left-sided colitis)	29 (42.6)	33 (46.5)
E3 (extensive colitis)	18 (26.5)	21 (29.6)
Mayo score	10 (9, 12)	10.5 (9, 12)	0.542
Geboes score	4 (3.8, 5)	4 (4, 4)	0.920
Interval from diagnosis to treatment initiation (weeks)	1.4 (1.0, 2.2)	1.2 (0.7, 2.0)	0.117
Disease severity			1.000
Moderate UC	36 (52.9)	38 (53.5)
Severe UC	32 (47.1)	33 (46.5)
Extraintestinal manifestations			0.850
Aphthous ulcers	3 (4.4)	2 (2.8)
Erythema nodosum	2 (2.9)	1 (1.4)
Peripheral arthritis	2 (2.9)	3 (4.2)
Laboratory findings
CRP (mg/dL)	28 (23.5, 35)	30 (25, 35)	0.058
Albumen (g/dL)	3 (2.5, 3.1)	3 (3, 3.3)	0.098
Fecal calprotectin (μg/g)	903 (800, 1100)	895 (700, 989)	0.137
Hb (g/dL)	11 (10, 12)	11 (10, 12)	0.787
Leucocytes (109/L)	10 (7, 11)	8 (7, 11)	0.829
Platelets (cm2)	250 (160, 450)	245 (170, 433)	0.847

Values present as n (%) were analyzed by χ² or Fisher’s exact tests. Values present as median (interquartile range) were analyzed by Mann-Whitney test. IFX: Infliximab; IVCS: Intravenous corticosteroids; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CRP: C-reactive protein; Hb: Hemoglobin.